LMR Partners’s Mustang Bio MBIO Stock Holding History

LMR Partners’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-47	Closed	-$17K	–	1199
2022 Q3	$17K	Hold	47	–	–	﹤0.01%	1174
2022 Q2	$21K	Buy	+47	New	+$26K	﹤0.01%	1230

Other funds holding MBIO

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

LMR Partners's MBIO Position: Q4 2022 in Review

LMR Partners sold out of Mustang Bio (MBIO) in Q4 2022, closing a stake of 47 shares — an estimated $17K sold.

LMR Partners first reported a position in MBIO in Q2 2022 and held it in 2 quarters. The position peaked at $21K in Q2 2022. 60 funds tracked by Wall St. Rank hold MBIO as of Q4 2022.

LMR Partners reported no remaining Mustang Bio position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 47 Mustang Bio shares in Q4 2022, an estimated $17K.
LMR Partners first reported a position in Mustang Bio in Q2 2022 and held it in 2 quarters.
LMR Partners's Mustang Bio position peaked at $21K in Q2 2022.
60 funds tracked by Wall St. Rank held Mustang Bio as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.